Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders

61-63

10.07.2009

Design using historical controls

Albert Yen, Ericka Simpson, Lanny Haverkamp, Stanley Appel

104-107

10.07.2009 · 31 Zitationen

MUNE

CL Gooch, JM Shefner

125-127

10.07.2009 · 2 Zitationen

North East ALS Study Group

Merit Cudkowicz, Jeremy Shefner

86-89

10.07.2009 · 4 Zitationen

Assessment of strength measurements

Eric J Sorensen

26-30

10.07.2009 · 1 Zitationen

Parkinson's disease

Stanley Fahn

84-85

10.07.2009 · 5 Zitationen

Maximum voluntary isometric contraction (MVIC)

Merit Cudkowicz, Hui Zhang, Muhammad Qureshi, David Schoenfeld

57-60

10.07.2009 · 14 Zitationen

Improving efficiency of ALS clinical trials using lead‐in designs

Dan H Moore II, Robert G Miller

6-7

10.07.2009

Preface

Hiroshi Mitsumoto, Serge Przedborski

118-120

10.07.2009 · 1 Zitationen

Sociology of collaborative research groups

Ira Shoulson

31-33

10.07.2009 · 2 Zitationen

Stroke

Jay P Mohr

43-45

10.07.2009 · 2 Zitationen

Statistical issues

Bruce Levin

90-93

10.07.2009 · 104 Zitationen

ALSFRS‐R

Paul H Gordon, Robert G Miller, Dan H Moore

34-35

10.07.2009 · 1 Zitationen

Neuro‐Oncology

S Clifford Schold Jr

128-128

10.07.2009 · 1 Zitationen

Great Lakes ALS Study Group

Eric Sorenson

36-41

10.07.2009

Regulatory issues in ALS clinical trials

Wilson W Bryan

133-134

10.07.2009 · 2 Zitationen

European ALS Consortium

Vincent Meininger

5-5

10.07.2009 · 1 Zitationen

Foreword

Gerald D. Fischbach

141-143

10.07.2009 · 2 Zitationen

Summing up: an action plan for ALS research

Lewis P Rowland

14-18

10.07.2009 · 3 Zitationen

Molecular targets for neuroprotection

Serge Przedborski

52-54

10.07.2009 · 6 Zitationen

ALS trial design: expectation and reality

Robert G Miller, Dan H Moore

76-78

10.07.2009 · 1 Zitationen

Disease‐modifying interventions

Edward Kasarskis

108-110

10.07.2009 · 56 Zitationen

The Neurophysiological Index in ALS

Michael Swash, Mamede de Carvalho

121-124

10.07.2009 · 4 Zitationen

Western ALS Study Group

R G Miller, D H Moore, C E Jackson, the WALS Study Group

19-21

10.07.2009 · 10 Zitationen

High throughput drug screening

Jill Heemskerk

79-83

10.07.2009 · 2 Zitationen

Survival

J Cedarbaum

111-114

10.07.2009 · 12 Zitationen

MRS

S Kalra, DL Arnold

46-47

10.07.2009

Data Safety Monitoring Board (DSMB)

KMA Welch

99-102

10.07.2009 · 22 Zitationen

Measuring pseudobulbar affect in ALS

Richard A Smith, James E Berg, Laura E Pope, Ronald A Thisted

129-132

10.07.2009 · 13 Zitationen

The National Registry of Veterans with Amyotrophic Lateral Sclerosis: Department of Veterans Affairs Cooperative Studies Program (CSP) #500a

Edward J Kasarkis, Kelli Dominic, Eugene Z Oddone

64-67

10.07.2009 · 1 Zitationen

Baseline disease characteristics

P N Leigh

115-117

10.07.2009 · 3 Zitationen

Drug cocktails

Jeffrey Rosenfeld

103-103

10.07.2009

Use of surrogate markers

Marc K Walton

94-98

10.07.2009 · 1 Zitationen

AALSS

Albert Yen, Ericka Simpson, Lanny Haverkamp, Stanley Appel

135-136

10.07.2009

Future national study group in ALS

Steven P Ringel

22-25

10.07.2009 · 5 Zitationen

Preclinical studies: how much can we rely on?

Jeffrey D Rothstein

42-42

10.07.2009

Randomized controlled trials

John Marler

8-13

10.07.2009 · 13 Zitationen

Randomized control trials in ALS: lessons learned

Hiroshi Mitsumoto, Paul Gordon, Petra Kaufmann, Clifton Gooch, Serge Przedborski, Lewis P Rowland

68-75

10.07.2009 · 7 Zitationen

Disease‐modifying drug therapies

Benjamin R Brooks, Mohammed Sanjak

137-140

10.07.2009 · 2 Zitationen

Patient orientated research and clinical trials

Walter G. Bradley

48-51

10.07.2009 · 6 Zitationen

Missing data

John LP Thompson, Gilberto Levy

55-56

10.07.2009 · 13 Zitationen

An efficient multi‐stage, single‐arm Phase II futility design for ALS

Yuko Y Palesch, Barbara C Tilley

255-256

10.07.2009 · 4 Zitationen

Randomised controlled trial in non-invasive ventilation: what trial?

Anabela Pinto, Mamede de Carvalho

202-207

10.07.2009 · 9 Zitationen

Sequential designs for clinical trials in amyotrophic lateral sclerosis

Geert Jan Groeneveld, Ingeborg van der Tweel, John HJ Wokke, Leonard H van den Berg

230-234

10.07.2009 · 20 Zitationen

Physical decline and quality of life in amyotrophic lateral sclerosis

Orla Hardiman, Anne Hickey, Lorna J. O'Donerty

250-254

10.07.2009 · 10 Zitationen

A Phase I safety study of hyperbaric oxygen therapy for amyotrophic lateral sclerosis

Julie Steele, Luis A Matos, Eustorgio A Lopez, Miguel A Perez-Pinzon, Ricardo Prado, Raul Busto, Kristopher L E Arheart, Walter G Bradley

240-244

10.07.2009 · 60 Zitationen

Changes in the management of ALS since the publication of the AAN ALS practice parameter 1999

W.G. Bradley, F. Anderson, N. Gowda, R.G. Miller, the ALS CARE Study Group

220-225

10.07.2009 · 9 Zitationen

CGP 3466B has no effect on disease course of (G93A) mSOD1 transgenic mice

Geert Groeneveld, Freek van Muiswinkel, Judith de Leeuw van Weenen, Hylke Blauw, Jan Veldink, John Wokke, Leonard van den Berg, Peter Bär

235-239

10.07.2009 · 37 Zitationen

Inter-evaluator reliability of the ALS Functional Rating Scale

Barbara Miano, Gregory Stoddard, Summer Davis, Mark Bromberg

226-229

10.07.2009 · 25 Zitationen

Development and implementation of the Dutch protocol for rehabilitative management in amyotrophic lateral sclerosis

JP van den Berg, IJM de Groot, BC Joha, JM van Haelst, P van Gorcom, S Kalmijn

245-249

10.07.2009 · 33 Zitationen

Depression and bulbar involvement in amyotrophic lateral sclerosis

Thomas Hillemacher, Elmar Gräßel, Sebastian Tigges, Stefan Bleich, Bernhard Neundörfer, Johannes Kornhuber, Martin Hecht

208-212

10.07.2009 · 113 Zitationen

Survival of 793 patients with amyotrophic lateral sclerosis diagnosed over a 28-year period

Daniela Testa, Roberta Lovati, Massimo Ferrarini, Fabrizio Salmoiraghi, Graziella Filippini

213-219

10.07.2009 · 169 Zitationen

Inflammation in amyotrophic lateral sclerosis spinal cord and brain is mediated by activated macrophages, mast cells and T cells

Michael Graves, Milan Fiala, Lu Anne Dinglasan, Nancy Liu, James Sayre, Francesco Chiappelli, Cees van Kooten, Harry Vinters

195-201

10.07.2009 · 37 Zitationen

Breaking the news in amyotrophic lateral sclerosis

Adriano Chiò, Gian Domenico Borasio

131-135

10.07.2009 · 72 Zitationen

Breaking the news: A survey of ALS patients and their caregivers

Leo Mccluskey, David Casarett, Andrew Siderowf

150-153

10.07.2009 · 25 Zitationen

Oropharyngeal dysphagia in amyotrophic lateral sclerosis: neurological and dysphagia specific rating scales

Deirdre Kidney, Michael Alexander, Bernie Corr, Orna O'Toole, Orla Hardiman

154-163

10.07.2009 · 25 Zitationen

Mirror movements and ipsilateral motor evoked potentials in ALS

Klaus Krampfl, Bahram Mohammadi, Leonid Komissarow, Reinhard Dengler, Johannes Bufler

136-140

10.07.2009 · 41 Zitationen

Corticospinal tract degeneration and possible pathogenesis in ALS evaluated by MR diffusion tensor imaging

Merete Karlsborg, Sverre Rosenbaum, Mette R Wiegell, Helle Simonsen, Henrik B W Larsson, Lene M Werdelin, Ole Gredal

180-187

10.07.2009 · 1 Zitationen

Selective vulnerability in amyotrophic lateral sclerosis: no evidence for a contribution of annexins, a family of calcium binding proteins

Stefan Probst‐Cousin, Markus Bergmann, Christian Maihöfner, Bernhard Neundörfer, Dieter Heuss

172-179

10.07.2009 · 23 Zitationen

(‐)‐Deprenyl alleviates the degenerative changes induced in the neonatal rat spinal cord by CSF from amyotrophic lateral sclerosis patients

Neelam Shahani, M Gourie‐Devi, A Nalini, Priti Y Rammohan, K Shobha, H N Harsha, T R Raju

188-191

10.07.2009 · 5 Zitationen

Motor neuron disease and optic neuropathy after acute exposure to a methanol‐containing solvent mixture

Adriano Chiò, Elena Herrero Hernandez, Gabriele Mora, Consuelo Valentini, Gianluigi Discalzi, Enrico Pira

164-171

10.07.2009 · 20 Zitationen

Temporal gene expression patterns in G93A/SOD1 mouse

Ling‐Chun Chen, Andrew P Smith, Yong Ben, Belma Zukic, Sheila Ignacio, Dan Moore, Nancy M Lee

141-149

10.07.2009 · 77 Zitationen

Reduced NAA in motor and non‐motor brain regions in amyotrophic lateral sclerosis: a cross‐sectional and longitudinal study

R R Rule, J Suhy, N Schuff, D F Gelinas, R G Miller, M W Weiner

120-129

10.07.2009

THEME 6 RESPIRATORY AND NUTRITIONAL MANAGEMENT

10.1080/17434470410003480

121-126

10.07.2009 · 25 Zitationen

Communication strategies of people with ALS and their partners

Joan Murphy

63-72

10.07.2009 · 1 Zitationen

THEME 1 HUMAN CELL BIOLOGY AND PATHOLOGY

10.1080/17434470410003435

72-83

10.07.2009 · 94 Zitationen

Nutritional management in MND/ALS patients: an evidence based review

Catherine Heffernan, Crispin Jenkinson, Tricia Holmes, Gene Feder, Richard Kupfer, P Nigel Leigh, Sue McGowan, Alan Rio, Paul Sidhu

118-120

10.07.2009 · 10 Zitationen

Interleukin‐12 and interferon‐γ are not detectable in the cerebrospinal fluid of patients with amyotrophic lateral sclerosis

Lara S Ford, Dominic B Rowe

130-135

10.07.2009

THEME 7 COGNITIVE AND PSYCHOLOGICAL ASSESSMENT AND SUPPORT

Papps B, Abrahams S, Wicks P, Leigh PN, Goldstein LH

7-60

10.07.2009

Platform Communications

10.1080/17434470410003516

107-117

10.07.2009 · 99 Zitationen

Efficacy and safety of xaliproden in amyotrophic lateral sclerosis: results of two phase III trials

Vincent Meininger, Gilbert Bensimon, Walter G Bradley, Benjamin R Brooks, Patrice Douillet, Andrew A Eisen, Lucette Lacomblez, P Nigel Leigh, Wim Robberecht

136-147

10.07.2009

THEME 8 RESEARCH TO IMPROVE STANDARDS OF CARE

10.1080/17434470410003507

99-106

10.07.2009 · 18 Zitationen

Xaliproden in amyotrophic lateral sclerosis: early clinical trials

Lucette Lacomblez, Gilbert Bensimon, Patrice Douillet, Valérie Doppler, François Salachas, Vincent Meininger

84-98

10.07.2009 · 47 Zitationen

Amyotrophic lateral sclerosis: a consensus viewpoint on designing and implementing a clinical trial

P Nigel Leigh, Michael Swash, Yasuo Iwasaki, Albert Ludolph, Vincent Meininger, Robert G Miller, Hiroshi Mitsumoto, Pamela Shaw, Kunio Tashiro, Leonard Van Den Berg

110-119

10.07.2009

THEME 5 DIAGNOSIS, PROGNOSIS AND DISEASE PROGRESSION

10.1080/17434470410003471

79-99

10.07.2009

THEME 3 IN VIVO EXPERIMENTAL MODELS

10.1080/17434470410003453

73-78

10.07.2009 · 4 Zitationen

THEME 2 GENETICS AND EPIDEMIOLOGY

Vance CA, Smith BN, Ruddy DM, Al-Chalabi A, Shaw CE

67-71

10.07.2009 · 36 Zitationen

Non‐invasive ventilation in ALS: current practice and future role

S C Bourke, G J Gibson

100-109

10.07.2009

THEME 4 IN VITRO EXPERIMENTAL MODELS

10.1080/17434470410003462

127-127

10.07.2009

Book review

10.1080/14660820310016930

46-54

10.07.2009 · 67 Zitationen

A longitudinal study of the evolution of cognitive function and affective state in patients with amyotrophic lateral sclerosis

M Kilani, J Micallef, C Soubrouillard, D Rey‐Lardiller, C Dematteï, M Dib, P Philippot, M Ceccaldi, J Pouget, O Blin

61-62

10.07.2009

Abrupt onset of progressive muscular atrophy

Raquel Gouveia, Teresinha Evangelista, Isabel Conceição, Anabela Pinto, Mamede de Carvalho

9-15

10.07.2009 · 39 Zitationen

Use of noninvasive ventilation in patients with amyotrophic lateral sclerosis

Noah Lechtzin, Charles M Wiener, Lora Clawson, Matthew C Davidson, Fred Anderson, Neelam Gowda, Gregory B Diette, the ALS CARE Study Group

16-21

10.07.2009 · 11 Zitationen

Long term proteasome inhibition does not preferentially afflict motor neurons in organotypical spinal cord cultures

Angela S Vlug, Dick Jaarsma

63-63

10.07.2009

Forthcoming meetings

10.1080/aml.5.1.63.63

55-60

10.07.2009 · 28 Zitationen

Validation of quality of life instruments in ALS

SC Bourke, E McColl, PJ Shaw, GJ Gibson

40-45

10.07.2009 · 35 Zitationen

Major stressors facing patients with amyotrophic lateral sclerosis (ALS): a survey to identify their concerns and to compare with those of their caregivers

Marilyn Trail, Naomi D Nelson, John N Van, Stanley H Appel, Eugene C Lai

6-8

10.07.2009 · 19 Zitationen

Ventilation in motor neuron disease: difficult decisions in difficult circumstances

David Oliver

26-32

10.07.2009 · 22 Zitationen

Dissociation between mechanical and myoelectrical manifestation of muscle fatigue in amyotrophic lateral sclerosis

M Sanjak, R Konopacki, R Capasso, KA Roelke, SM Peper, AM Houdek, A Waclawik, BR Brooks

22-25

10.07.2009 · 29 Zitationen

Astrogliosis in ALS: possible interpretations according to pathogenetic hypotheses

Davide Schiffer, Valentina Fiano

33-39

10.07.2009 · 103 Zitationen

Amyotrophic lateral sclerosis: delayed disease progression in mice by treatment with a cannabinoid

Chandrasekaran Raman, Sean D McAllister, Gulrukh Rizvi, Sonal G Patel, Dan H Moore, Mary E Abood